Drug Trial Radar · NCT07040280
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 20, 2026
Primary completion
Mar 1, 2031
Study completion Mar 1, 2033
Sponsor
- Lead sponsor
- ECOG-ACRIN Cancer Research GroupResearch network
- Sponsor type
- Research network
- First posted
- Jun 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well sulforaphane works in preventing melanoma in patients with multiple atypical moles (nevi) and a prior history of melanoma. Patients with a history of melanoma and multiple atypical nevi are at a significantly increased risk of developing additional melanomas than those without atypical nevi. Prevention measures usually include sun protection, monthly skin self-examinations and regular skin examinations from a doctor. Sulforaphane is a naturally-occurring substance found in many cruciferous vegetables, including broccoli, that may prevent melanoma from forming.
Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8
- Clinical Stage I Cutaneous Melanoma AJCC v8
- Clinical Stage II Cutaneous Melanoma AJCC v8
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Cutaneous Dysplastic Nevus
Interventions
Biopsy ProcedureProcedure
Undergo optional excisional biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Placebo AdministrationDrug
Given PO
SulforaphaneDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in total area of atypical and common pigmented nevocellular nevi on the posterior trunkTime frame: From baseline to 12 months after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.